quizartinib for frontline flt3-itd aml: updated results from the quantum-first trial
Published 9 months ago • 451 plays • Length 2:35Download video MP4
Download video MP3
Similar videos
-
1:55
assessing flt3-itd-specific mrd clearance using a pcr-ngs assay in the quantum-first trial
-
9:44
an update on the quantum-first trial: quizartinib plus chemotherapy in flt3-mutated aml
-
1:39
quantum-first: flt3-itd-specific mrd clearance is associated with improved os in newly diagnosed aml
-
3:03
quantum-first: flt3-itd-specific mrd to assess benefits of quizartinib in flt3-itd aml
-
3:31
update on quantum-first: quizartinib soc chemotherapy & as continuation therapy in flt3-itd aml
-
3:42
further analysis of quantum-first: the impact of allo-hct combined with quizartinib in flt3-itd aml
-
1:12
the value of flt3 inhibitors in aml and focus for future trial designs
-
1:27
quizartinib, venetoclax, and decitabine in patients with flt3-itd aml: a phase i/ii trial
-
11:41
kuliah hematology analyzer
-
4:22
icount 3ts - 3 part hematology system 7 reasons for you to choose ! 70 tests per hour !
-
![mixed leukocyte reaction and other antigen-presentation assays [webinar]](https://i.ytimg.com/vi/vCt7JToKeMk/mqdefault.jpg)
18:55
mixed leukocyte reaction and other antigen-presentation assays [webinar]
-
1:07
quantum-first: the benefit of quizartinib based on pre-transplant mrd status
-
2:54
quantum-first: association between flt3-itd-specific mrd clearance and survival in patients with aml
-
1:59
tangible benefit for flt3-itd r/r aml on quizartinib
-
1:43
lba: gilteritinib as post-transplant maintenance therapy in flt3-itd aml
-
5:24
safety by treatment phase and age when treating flt3-itd-mutated aml with quizartinib and chemo
-
1:40
second-generation flt3 inhibitors in the treatment of flt3-itd aml
-
0:35
management & outcome of patients with cbf aml and flt3-itd
-
2:40
an overview of the safety profile of flt3 inhibitors in aml
-
4:09
quantum-r: quizartinib looks promising for flt3-itd mutated aml
-
1:28
quizartinib provides clinical benefit in r/r flt3-itd aml
-
4:15
phase ib/ii trial of quizartinib, decitabine and venetoclax in flt3-itd-mutated aml